newborn screening programme
Duchenne muscular dystrophy
The muscular dystrophies are a group of genetic disorders. They cause progressive weakness. Some are severe and limit life expectancy whilst others relatively mild. Some people with the disorder may have no family history of a similar condition.
UK NSC screening recommendation
Newborn screening for Duchenne Muscular Dystrophy (DMD) is not recommended because:
- there is not a reliable test
- the best age to start treatment is not known
- there is a lack of evidence that screening and early treatment would improve the long term health of babies
Supporting documents from the 2016 review
Evidence summary Duchenne Muscular Dystrophy (2016)
This document provides the evidence on which the current UK NSC recommendation is based.
UK NSC coversheet & consultation responses Duchenne Muscular Dystrophy (2016)
This document summarises the review process including the public consultation comments.
Date previous review completed: 2016
Next review estimated to be completed: 2021 to 2022.
To see previous evidence reviews, visit the UK NSC archive.
Organisations interested in Duchenne muscular dystrophy
These organisations have expressed interest in this recommendation and may submit responses to evidence reviews.
List of organisations
- Action Duchenne
- ArchAngel MLD Trust
- British Association of Perinatal Medicine
- Duchenne Family Support Group
- Faculty of Public Health
- Genetic Alliance UK
- Institute of Child Health
- Metabolic Support UK
- Muscular Dystrophy UK
- Royal College of General Practitioners
- Royal College of Midwives
- Royal College of Paediatrics and Child Health
- Royal College of Physicians
- Royal College of Physicians and Surgeons of Glasgow
- Royal College of Physicians of Edinburgh